Strategic Advancements and Expanding Coverage Propel Plus Therapeutics’ Growth Potential
Jason McCarthy from Maxim Group maintains a Buy rating on Plus Therapeutics with a $3.00 price target, citing strategic advancements and expanded coverage for their CNSide test. Recent agreements with major insurers have increased coverage to 67 million lives, enhancing revenue potential. Plus Therapeutics is well-positioned to address unmet needs in the LM market, supported by a scalable testing infrastructure and promising study results.
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Plus Therapeutics, with a price target of $3.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors including Plus Therapeutics’ strategic advancements and expanding coverage for their CNSide test. The recent agreements with major insurers like Humana and UnitedHealthcare have significantly increased the coverage to 67 million lives, which is crucial for unlocking the revenue potential of CNSide.
Additionally, CNSide offers a more sensitive and informative diagnostic tool for leptomeningeal metastases compared to the current standard of care, which could lead to better treatment outcomes. Plus Therapeutics has also made strides in establishing a scalable testing infrastructure and implementing a market access strategy, which includes securing reimbursement codes and a value-based pricing framework. These efforts, alongside the promising results from the FORESEE study, position Plus Therapeutics well to capitalize on the unmet needs in the LM market.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and Medicus Pharma Ltd. According to TipRanks, McCarthy has an average return of -19.0% and a 29.78% success rate on recommended stocks.
